Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
735
archived clinical trials in
Thyroid Cancer

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility 1
2006
mi
from 43215
Seattle, WA
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility 1
2006
mi
from 43215
Seattle, WA
Click here to add this to my saved trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility 1
164
mi
from 43215
Morgantown, WV
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility 1
164
mi
from 43215
Morgantown, WV
Click here to add this to my saved trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility 1
334
mi
from 43215
Milwaukee, WI
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility 1
334
mi
from 43215
Milwaukee, WI
Click here to add this to my saved trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Facility 1
mi
from 43215
Rosario,
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Facility 1
mi
from 43215
Rosario,
Click here to add this to my saved trials
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Emory University Hospital Midtown
434
mi
from 43215
Atlanta, GA
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Emory University Hospital Midtown
434
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Emory University/Winship Cancer Institute
432
mi
from 43215
Atlanta, GA
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Emory University/Winship Cancer Institute
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Cancer Institute
166
mi
from 43215
Pittsburgh, PA
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Cancer Institute
166
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
537
mi
from 43215
New Haven, CT
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
537
mi
from 43215
New Haven, CT
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
163
mi
from 43215
Detroit, MI
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
163
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
482
mi
from 43215
Bronx, NY
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
482
mi
from 43215
Bronx, NY
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1947
mi
from 43215
Encinitas, CA
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1947
mi
from 43215
Encinitas, CA
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
411
mi
from 43215
Salisbury, MD
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
411
mi
from 43215
Salisbury, MD
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
161
mi
from 43215
Dearborn, MI
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
161
mi
from 43215
Dearborn, MI
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
682
mi
from 43215
Omaha, NE
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
682
mi
from 43215
Omaha, NE
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
414
mi
from 43215
Syracuse, NY
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
414
mi
from 43215
Syracuse, NY
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
354
mi
from 43215
Durham, NC
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
422
mi
from 43215
Goldsboro, NC
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
422
mi
from 43215
Goldsboro, NC
Click here to add this to my saved trials
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated:  12/31/1969
Research Site
1001
mi
from 43215
Québec,
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Status: Enrolling
Updated: 12/31/1969
Research Site
1001
mi
from 43215
Québec,
Click here to add this to my saved trials
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC)
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
A Targeted Ph I/II Trial of ZD6474 (Vandetanib; CAPRELSA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Ca (MTC)
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)
Comparison of I-124 and I-131 Radiopharmacokinetics in Patients Who Have Well-differentiated Thyroid Cancer and Are Prepared With Recombinant Human TSH Injection (rhTSH)
Status: Enrolling
Updated:  12/31/1969
MedStar Washington Hospital Center
328
mi
from 43215
Washington,
Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)
Comparison of I-124 and I-131 Radiopharmacokinetics in Patients Who Have Well-differentiated Thyroid Cancer and Are Prepared With Recombinant Human TSH Injection (rhTSH)
Status: Enrolling
Updated: 12/31/1969
MedStar Washington Hospital Center
328
mi
from 43215
Washington,
Click here to add this to my saved trials
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Mt. Sinai Medical Center
480
mi
from 43215
New York, NY
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Mt. Sinai Medical Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
995
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Rockville Centre
496
mi
from 43215
Rockville Centre, NY
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Rockville Centre
496
mi
from 43215
Rockville Centre, NY
Click here to add this to my saved trials
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering at Basking Ridge
449
mi
from 43215
Basking Ridge, NJ
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering at Basking Ridge
449
mi
from 43215
Basking Ridge, NJ
Click here to add this to my saved trials
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
515
mi
from 43215
Commack, NY
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
515
mi
from 43215
Commack, NY
Click here to add this to my saved trials
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
487
mi
from 43215
Sleepy Hollow, NY
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
487
mi
from 43215
Sleepy Hollow, NY
Click here to add this to my saved trials
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memoral Sloan Kettering Cancer Center
449
mi
from 43215
Basking Ridge, NJ
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memoral Sloan Kettering Cancer Center
449
mi
from 43215
Basking Ridge, NJ
Click here to add this to my saved trials
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
515
mi
from 43215
Commack, NY
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
515
mi
from 43215
Commack, NY
Click here to add this to my saved trials
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
480
mi
from 43215
New York, NY
Click here to add this to my saved trials
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Westchester
493
mi
from 43215
Harrison, NY
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
493
mi
from 43215
Harrison, NY
Click here to add this to my saved trials
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
675
mi
from 43215
Jacksonville, FL
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
675
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
559
mi
from 43215
Rochester, MN
Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
559
mi
from 43215
Rochester, MN
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham Cancer Center
492
mi
from 43215
Birmingham, AL
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham Cancer Center
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Kirklin Clinic at Acton Road
492
mi
from 43215
Birmingham, AL
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Kirklin Clinic at Acton Road
492
mi
from 43215
Birmingham, AL
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Joseph's Hospital and Medical Center
1662
mi
from 43215
Phoenix, AZ
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Joseph's Hospital and Medical Center
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology - Deer Valley Center
1662
mi
from 43215
Phoenix, AZ
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology - Deer Valley Center
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Services Foundation
1648
mi
from 43215
Scottsdale, AZ
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Services Foundation
1648
mi
from 43215
Scottsdale, AZ
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Auburn
2016
mi
from 43215
Auburn, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Auburn
2016
mi
from 43215
Auburn, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Alta Bates Summit Medical Center-Herrick Campus
2097
mi
from 43215
Berkeley, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Alta Bates Summit Medical Center-Herrick Campus
2097
mi
from 43215
Berkeley, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
2015
mi
from 43215
Cameron Park, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
2015
mi
from 43215
Cameron Park, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Eden Hospital Medical Center
2091
mi
from 43215
Castro Valley, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Eden Hospital Medical Center
2091
mi
from 43215
Castro Valley, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Roseville
2028
mi
from 43215
Roseville, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Roseville
2028
mi
from 43215
Roseville, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center at Mount Zion
2108
mi
from 43215
San Francisco, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center at Mount Zion
2108
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center-Pacific Campus
mi
from 43215
San Francisco, CA
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center-Pacific Campus
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials